静脉血栓栓塞症患者谁应接受长期抗凝治疗及用何种药物?
针对静脉血栓栓塞症(VTE)初始抗凝3至6个月后的决策困境,本文讨论是否继续长期抗凝及选择何种抗凝药,指出长期风险(主要为严重出血)与获益(减少复发VTE)的估计存在不确定性且权衡紧密,并介绍作者临床实践中的做法。
要点
- VTE初始抗凝3至6个月后需决策是否停止或无限期继续抗凝。
- 多数日常实践场景中,长期严重出血风险与减少复发VTE获益的估计存在不确定性,权衡紧密。
- 决定继续抗凝后,抗凝药选择同样因疗效与安全性估计不确定而困难。
核心结论
- VTE初始抗凝3至6个月后,是否停止或无限期继续抗凝及选择何种抗凝药,在多数日常实践场景中因长期风险与获益估计的不确定性及紧密权衡而具有挑战性。
研究设计与样本
- 本文为综述,讨论VTE初始抗凝3至6个月后长期抗凝决策及抗凝药选择,并介绍作者临床实践中的做法。
主要发现
- 部分场景决策容易,例如大手术诱发的VTE应停止抗凝。
- 多数日常实践场景中,长期风险(主要为严重出血)与获益(减少复发VTE)的估计存在不确定性,且两者权衡紧密。
- 决定继续抗凝后,抗凝药选择因疗效与安全性估计的不确定性及选择间紧密权衡而困难。
临床怎么用
- 作者在文末介绍了其临床实践中的做法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is "Which anticoagulant?" Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.
引用
- Rodger MA, Le Gal G. Who should get long-term anticoagulant therapy for venous thromboembolism and with what? Blood Adv. 2018. PMID: 30425073. doi:10.1182/bloodadvances.2018020230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。